Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_assertion type Assertion NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_head.
- NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_assertion wasGeneratedBy ECO_0000203 NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_provenance.
- NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_assertion wasDerivedFrom befree-20150227 NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_provenance.
- NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_assertion SIO_000772 14976243 NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_provenance.
- NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_assertion evidence source_evidence_literature NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_provenance.
- NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_assertion description "[The ABL inhibitor Imatinib (Gleevec, STI571) has remarkable efficacy for treating chronic phase CML, and FLT3 inhibitors (e.g., PKC412) show similar promise in preclinical studies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP576965.RAVxa6VkICVhsE_Ue8JGrzKLtbMOeHirau6TZj2bLLRrk130_provenance.